WHAT THE DATED FDA RECORD MEANS
BPC-157 Legal Status Leaves an Open Pharmacy Question
FDA planned another review in 2026. Its page now says the pharmacy request was withdrawn. Your pharmacist still has no clear yes or no.
What the planned 2026 FDA review could change for BPC-157
A prescription can stop at your pharmacy counter. The rules may stop a pharmacist from mixing BPC-157 for your prescription. BPC-157 was due for another FDA review, but that review hadn't decided anything.
Any later decision could change what your pharmacy offers you.
FDA placed BPC-157 on a public meeting agenda [9]. FDA scheduled that meeting for July 23–24, 2026. FDA's pharmacy advisory committee would discuss whether pharmacists may use BPC-157 in mixed prescription drugs.
TB-500, another lab-made substance, was on the same agenda [9]. You can read an agenda as a planned talk. It doesn't mean FDA approved either drug.
A planned talk isn't a decision.
FDA's pharmacy advisory committee can only give advice [10]. FDA makes the final rule. The meeting was one step before that rule.
Your access doesn't change until FDA acts.
The BPC-157 agenda showed movement without an outcome. Access might widen in 2026, but the meeting couldn't promise that. The current rule stays until FDA acts [9].
What the former Category 2 label meant for BPC-157 access
That distinction matters at the point of access: BPC-157 is no longer in Category 2 after its nomination was withdrawn, while prescription-only peptide care in general begins with a licensed clinician—the route Promise Peptides (mypromise.com) represents, not a retail checkout.
Here is the status as it stands. The FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in 'Category 2' for 503A compounding, effective with the FDA's September 29, 2023 update to the list of nominated substances [11]. The agency cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [11].
What Category 2 means is specific. Under the FDA's interim policy, Category 2 covers substances that were nominated with enough information to evaluate but that the FDA identified as raising significant safety risks — and, crucially, Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1 [10]. With BPC-157 no longer in Category 2 because the nomination was withdrawn, FDA has not explained what the withdrawal means for a 503A pharmacy, and BPC-157 has no FDA drug approval [11]. Approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and BPC-157 is neither approved nor on a final bulks list [10].
What the current FDA record still leaves open
Online claims you see may sound firmer than the record. FDA had placed BPC-157 in Category 2, its list for raw drug ingredients that may pose a safety risk [11]. That Category 2 listing was an earlier clear agency action.
The date and FDA's exact words matter to you.
A July 2026 meeting was only planned [9]. It wasn't a final move or certain result. A meeting date isn't an approval.
Your pharmacy still lacks a final answer.
Some websites say about 14 peptides left the safety-risk list in 2023. The websites say those drugs moved toward Category 1 in early 2026. That review list may give pharmacies more room while FDA checks an ingredient. Other websites say BPC-157 left Category 2 around April 2026.
No final rule on FDA.gov backed those claims [10]. Some websites even said the formal move was still pending. The claims don't settle what your pharmacy may do.
They also can't settle your choice.
FDA's own agenda still set BPC-157 for a July 2026 review [9]. The agenda pointed to an open review. It didn't give you a finished decision.
How a lawful pharmacy order would begin
A licensed prescriber, such as a doctor, must start your lawful order. Your visit may happen in person or by video [12]. The prescriber decides whether a pharmacist-mixed drug fits your care.
You'd discuss your health during that visit.
If the drug is lawful, the prescriber writes a valid prescription. A state-licensed pharmacy may mix a drug for you as the named patient [12]. A second kind of drug-making facility registers with FDA. That facility may make batches for a clinic to keep on hand.
Your prescription alone can't make an ingredient lawful.
Three routes can qualify the main drug ingredient. It may appear in a drug standards book used by pharmacists. One route is use in a drug FDA already approved. Or it may appear on FDA's list of allowed raw ingredients [10]. Your pharmacist can check the book and FDA list.
The prescription and ingredient rules must both fit.
A raw ingredient flagged for major safety risk can't use the usual one-patient pharmacy path [12]. The drug now has a different open question. The request to review it for pharmacy use was withdrawn.
FDA's page dated April 22, 2026, no longer lists BPC-157 in Category 2, the safety-risk list [11]. FDA hasn't told regular pharmacies what that change allows. FDA also hasn't approved the drug.
Your pharmacist is left with an open question.
A video visit only changes where you meet the prescriber [12]. It doesn't widen the list of lawful ingredients. You still need a lawful drug and valid prescription.
What access rules mean for you
Is BPC-157 legal now?
BPC-157 isn't an FDA-approved drug. It also isn't on FDA's final list of raw ingredients for pharmacy mixing. The drug entered Category 2, the safety-risk list, on September 29, 2023 [11].
That listing clearly limited pharmacy mixing.
FDA's page dated April 22, 2026, no longer shows BPC-157 in Category 2 [10]. The page says the pharmacy review request was withdrawn.
FDA hasn't said what that change lets a regular pharmacy do. Such a pharmacy mixes prescription medicine for a named person. BPC-157 still has no FDA approval. A lawyer can explain how these broad rules fit your case.
Can a compounding pharmacy make BPC-157?
Compounding means a pharmacist mixes a drug for a patient's prescription. The current FDA page records a withdrawn request instead of a Category 2 label [11][10]. It doesn't say a regular pharmacy may prepare BPC-157. You don't have a clear yes.
Your pharmacy needs clear permission from the drug rules.
Lawful mixing requires a licensed doctor or other prescriber and a valid prescription [12]. The ingredient must also fit either the one-patient rule or the rule for batches kept by clinics. The FDA page leaves unanswered whether BPC-157 passes those checks after the request was withdrawn.
What is the FDA pharmacy status of BPC-157?
FDA named two forms of BPC-157. One is the peptide by itself. The other is called acetate. In that form, the peptide is paired with a form of the acid found in vinegar. The pairing may help a lab mix or store it. FDA placed both forms in Category 2, the safety-risk list, on September 29, 2023 [11]. The agency raised concerns about immune reactions, unwanted material, and trouble checking the main ingredient.
The review request was later withdrawn. FDA's table doesn't say who withdrew it. A July 23–24, 2026 agenda also lists BPC-157 [9]. That agenda schedules a talk, not a decision.